Ardelyx, Inc. (ARDX)
3.75
-0.05
(-1.32%)
USD |
NASDAQ |
Sep 03, 10:01
Ardelyx Research and Development Expense (TTM) : 83.87M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 83.87M |
| March 31, 2026 | 73.40M |
| December 31, 2025 | 68.47M |
| September 30, 2025 | 59.68M |
| June 30, 2025 | 57.29M |
| March 31, 2025 | 54.45M |
| December 31, 2024 | 50.25M |
| September 30, 2024 | 46.26M |
| June 30, 2024 | 39.84M |
| March 31, 2024 | 35.29M |
| December 31, 2023 | 34.24M |
| September 30, 2023 | 34.12M |
| June 30, 2023 | 32.61M |
| March 31, 2023 | 34.53M |
| December 31, 2022 | 34.06M |
| September 30, 2022 | 45.80M |
| June 30, 2022 | 62.19M |
| March 31, 2022 | 78.28M |
| December 31, 2021 | 89.70M |
| September 30, 2021 | 86.60M |
| June 30, 2021 | 75.17M |
| March 31, 2021 | 67.91M |
| December 31, 2020 | 63.23M |
| September 30, 2020 | 57.44M |
| Date | Value |
|---|---|
| June 30, 2020 | 63.22M |
| March 31, 2020 | 64.30M |
| December 31, 2019 | 69.33M |
| September 30, 2019 | 79.47M |
| June 30, 2019 | 79.83M |
| March 31, 2019 | 76.40M |
| December 31, 2018 | 69.37M |
| September 30, 2018 | 64.50M |
| June 30, 2018 | 61.32M |
| March 31, 2018 | 65.85M |
| December 31, 2017 | 74.88M |
| September 30, 2017 | 83.93M |
| June 30, 2017 | 94.03M |
| March 31, 2017 | 97.30M |
| December 31, 2016 | 94.16M |
| September 30, 2016 | 80.73M |
| June 30, 2016 | 70.58M |
| March 31, 2016 | 52.94M |
| December 31, 2015 | 39.88M |
| September 30, 2015 | 34.39M |
| June 30, 2015 | 25.30M |
| March 31, 2015 | 24.23M |
| December 31, 2014 | 25.60M |
| September 30, 2014 | 24.25M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| REGENXBIO, Inc. | 213.77M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Anika Therapeutics, Inc. | 27.45M |
| Savara, Inc. | 86.84M |